Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.54 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.54 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.46 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.45 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3316834 | 1.00 | ADORA3 (0.62) | ADORA3ADORA2AADORA2BADORA1PDE4A | |
| SCHEMBL3316851 | 1.00 | ADORA3 (0.62) | ADORA3ADORA2AADORA2BADORA1PDE4A | |
| SCHEMBL3313727 | 0.86 | ADORA3 (0.53) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL3313715 | 0.86 | ADORA3 (0.53) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL13396844 | 0.86 | ADORA3 (0.53) | ADORA3ADORA2AADORA2BADORA1 | |
| SCHEMBL13396504 | 0.85 | AHCY (0.53) | ADORA1PDE4DP2RY1 | |
| SCHEMBL3320956 | 0.85 | AHCY (0.53) | ADORA1PDE4DP2RY1 | |
| SCHEMBL3317095 | 0.85 | AHCY (0.53) | ADORA1PDE4DP2RY1 | |
| SCHEMBL13415621 | 0.82 | ADORA3 (0.44) | ADORA3ADORA2AADORA2BADORA1PDE4A | |
| SCHEMBL13415712 | 0.82 | YTHDC1 (0.51) | ADORA3ADORA2AADORA2BADORA1PDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8324179-B2 | Nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| WO-2008100447-A2 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104532-A1 | NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | SLC29A1, NUDT1, EIF2AK2 | ADORA3 462/4885ADORA2A 545/4885ADORA2B 873/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.